Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • Tyrosine Kinases
    (64)
  • JAK
    (33)
  • VEGFR
    (26)
  • Apoptosis
    (19)
  • EGFR
    (17)
  • PDGFR
    (17)
  • FLT
    (15)
  • Autophagy
    (13)
  • Src
    (11)
  • Others
    (53)
Filter
Search Result
Results for "

Tyrosine Kinases

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    198
    TargetMol | Inhibitors_Agonists
  • Compound Libraries
    2
    TargetMol | Compound_Libraries
  • Peptide Products
    2
    TargetMol | Peptide_Products
  • Inhibitory Antibodies
    1
    TargetMol | Inhibitory_Antibodies
  • Dye Reagents
    1
    TargetMol | Dye_Reagents
  • PROTAC Products
    4
    TargetMol | PROTAC
  • Natural Products
    12
    TargetMol | Natural_Products
  • Recombinant Protein
    47
    TargetMol | Recombinant_Protein
  • Isotope Products
    8
    TargetMol | Isotope_Products
Gefitinib
ZD1839
T1181184475-35-2
Gefitinib (ZD1839) is an EGFR first-generation inhibitor with oral activity that inhibits the EGFR 19 Del and L858R mutations. Gefitinib has antitumor activity and is used for the treatment of EGFR-mutated non-small-cell lung cancers. Gefitinib administration RESULTS in the development of the EGFR C797S resistance mutation.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Hot
Ruxolitinib
INCB018424, (R)-Ruxolitinib
T1829941678-49-5
Ruxolitinib (INCB018424) is a JAK1 2 inhibitor (IC50=3.3 2.8 nM) that is potent and selective. Rixolitinib exhibits antitumor activity and induces autophagy and apoptosis.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Hot
Deucravacitinib
BMS-986165
T146871609392-27-9
Deucravacitinib (BMS-986165) is a highly selective, orally bioavailable, allosteric TYK2 inhibitor for the treatment of autoimmune diseases. It blocks receptor-mediated Tyk2 activation by stabilizing the regulatory JH2 domain, inhibiting IL-12 23 and type I IFN pathways. It selectively binds to the TYK2 pseudokinase (JH2) domain with an IC50 of 1.0 nM.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Hot
Ibrutinib
PCI-32765
T1835936563-96-1
Ibrutinib (PCI-32765) is an irreversible inhibitor of BTK (IC50: 0.5 nM) that selectively blocks B cell activation.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Hot
Baricitinib
LY3009104, INCB028050
T24851187594-09-7
Baricitinib (INCB028050) is a JAK1 and JAK2 inhibitor (IC50=5.9 5.7 nM) with selective and oral activity. Baricitinib has potential anti-inflammatory, immunomodulatory and anti-tumor activity.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Hot
Zongertinib
BI 764532, BI 1810631
T695342728667-27-2In house
Zongertinib is a human HER2-selective tyrosine kinase inhibitor, a novel TK that is highly selective for covalent binding to the HER2 tyrosine kinase domain (TKD).Zongertinib exhibits antitumor activity with inhibitory effects on pHER2 and EGF.
  • Inquiry Price
8-10 weeks
Size
QTY
TargetMol | Inhibitor Hot
Vidarabine
Vira-A, Arabinosyladenine, Ara-A, Adenine Arabinoside, 9-β-D-Arabinofuranosyladenine
T15065536-17-4
Vidarabine (Adenine Arabinoside) is a nucleoside antibiotic isolated from Streptomyces antibioticus. It has some antineoplastic properties and has broad spectrum activity against DNA viruses in cell cultures and significant antiviral activity against infections caused by a variety of viruses such as the herpes viruses, the VACCINIA VIRUS and varicella zoster virus.
  • Inquiry Price
Size
QTY
Pyridone 6
Janus-Associated Kinase Inhibitor I, JAK Inhibitor I, JAK I inhibitor, CMP 6
T3080457081-03-7
Pyridone 6 (JAK Inhibitor)(CMP 6) is a potent and selective inhibitor of JAK1 (IC50=15 nM, murine JAK1), JAK2 (IC50=1 nM), JAK3 (Ki=5 nM), and Tyk2 (IC50=1 nM); displaying significantly weaker affinities (130 nM to 10 mM) for other protein tyrosine kinases.
  • Inquiry Price
Size
QTY
Pacritinib
SB1518
T6020937272-79-2
Pacritinib (SB1518) (SB1518) is an effective and specific inhibitor of JAK2 and FLT3 (IC50: 23 22 nM, in cell-free assays).
  • Inquiry Price
Size
QTY
su 4981
3-(4-Morpholinobenzylidene)indolin-2-one
T60094186610-88-8
SU 4981 is an inhibitor of VEGFR and a modulator of tyrosine kinase activity.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
Cerdulatinib hydrochloride
PRT2070 hydrochloride, PRT062070 hydrochloride
T61041369761-01-2
Cerdulatinib hydrochloride (PRT2070 hydrochloride) is an oral active, multi-targeted tyrosine kinase inhibitor with IC50 of 12 nM 6 nM 8 nM 0.5 nM and 32 nM for JAK1 JAK2 JAK3 TYK2 and Syk, respectively. Also inhibits 19 other tested kinases with IC50 less than 200 nM.
  • Inquiry Price
7-10 days
Size
QTY
TargetMol | Inhibitor Sale
Ilginatinib hydrochloride
NS-018 hydrochloride
T12266L21239358-85-0
Ilginatinib hydrochloride (NS-018 hydrochloride) is a highly active, orally bioavailable JAK2 inhibitor.
  • Inquiry Price
Size
QTY
Delgocitinib
JTE-052, Corectim(Delgocitinib)
T150961263774-59-9
Delgocitinib (JTE-052) is a specific JAK (Janus kinase) inhibitor with IC50 values of 2.8, 2.6, 13, and 58 nM for JAK1, JAK2, JAK3, and Tyk2 respectively. Delgocitinib is involved in various inflammatory and autoimmune diseases through JAK-dependent cytokines and can effectively suppress multiple cytokine signaling while inhibiting itching caused by cytokines. It is widely used to treat various inflammatory diseases, including autoimmune diseases and hypersensitivity reactions.
  • Inquiry Price
Size
QTY
Baricitinib phosphate
LY-3009104 phosphate, INCB-028050 phosphate, Baricitinib Phosphate
T23601187595-84-1
Baricitinib phosphate (INCB028050) is a selective orally bioavailable JAK1 JAK2 inhibitor.
  • Inquiry Price
Size
QTY
Cerdulatinib
PRT2070, PRT062070
T24871198300-79-6
Cerdulatinib (PRT2070) is an novel oral dual Syk JAK inhibitor.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
Decernotinib
VX-509, VRT-831509
T2636944842-54-0
Decernotinib (VRT-831509)(VX-509; VRT-831509) is a potent and selective Janus kinase 3 (JAK3) inhibitor with Ki of 2.5 nM; IC50 is 50-170 nM in cellular assays.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
HNMPA-(AM)3
T36584120944-03-8
HNMPA-(AM)3 inhibits activation of ERK phosphorylation and stimulation of ecdysteroid production by prothyrotropin (PTTH). Furthermore, HNMPA-(AM)3 had inhibitory effects on ecdysteroid production (IC50=14.2 μM) and insulin receptor activity (IC50=14.2 μM and 200 μM, in mosquitoes and mammals, respectively).
  • Inquiry Price
7-10 days
Size
QTY
Syk Inhibitor II dihydrochloride
Syk Inhibitor II (hydrochloride)
T4391227449-73-2
Spleen tyrosine kinase (Syk) is a non-receptor tyrosine kinase that, upon phosphorylation, binds to immunoreceptor tyrosine-based activation motifs of FcRγ chains and mediates downstream signaling related to platelet function and inflammation. Syk inhibit
  • Inquiry Price
Size
QTY
Hypericin
Hypericine, Cyclosan
T6S0923548-04-9
Hypericin (Cyclosan) is a natural anthraquinone compound, an extract of Hypericum perforatum, which inhibits PKC, MAO, dopamine-beta-hydroxylase, reverse transcriptase, telomerase, and CYP, etc. Hypericin exhibits antimicrobial, antiviral, antitumor, and antidepressant activities.
  • Inquiry Price
Size
QTY
larotinib
T733341438072-11-7
Larotinib is an orally active, potent, and broad-spectrum tyrosine kinase inhibitor (TKI) with an IC50 of 0.6 nM for EGFR.
  • Inquiry Price
6-8 weeks
Size
QTY
Ginsenoside Ra1
TN109683459-41-0
Ginsenoside Ra1, a component from ginseng, exhibits significant inhibitory effects on protein tyrosine kinase (PTK) activation induced by hypoxia reoxygenation (H R).
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
Tafetinib
SIM-010603, SIM010603, SIM 010603
T289111032265-57-8In house
Tafetinib (SIM-010603) is a novel potent and orally available tyrosine kinase inhibitor with anti-angiogenic and anti-tumour activity.
  • Inquiry Price
6-8weeks
Size
QTY
JAK-IN-21
T614942445499-20-5
JAK-IN-21 is a selective and potent JAK inhibitor that inhibits JAK1, JAK2, J2V617F and TYK2 with IC50 values of 1.73, 2.04, 109 and 62.9 nM, respectively.
  • Inquiry Price
6-8 weeks
Size
QTY
TargetMol | Inhibitor Sale
GTP-14564
T7185734823-86-4
GTP-14564 is a novel tyrosine kinase inhibitor that also inhibits wt-FLT3 and ITD-FLT3. GTP-14564 inhibits the growth of interleukin-3-independent Ba F1 expressing ITD-FLT3 at 3 μ m, whereas a 30-fold higher concentration of GTP-14564 is required to inhibit the FLT3 ligand-dependent growth (wt-FLT3) of Ba F3 expressing wild-type FLT3. F3 expressing wild-type FLT3 (wt-FLT3).
  • Inquiry Price
6-8 weeks
Size
QTY
TargetMol | Inhibitor Sale